CompletedPhase 2NCT00963053

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

Studying Oculocerebral hypopigmentation syndrome, Cross type

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vantia Ltd
Principal Investigator
David Bell
Bio-Kinetic Europe Limited
Intervention
VA111913 TS and placebo(drug)
Enrollment
146 target
Eligibility
18-35 years · FEMALE
Timeline
20092010

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00963053 on ClinicalTrials.gov

Other trials for Oculocerebral hypopigmentation syndrome, Cross type

Additional recruiting or active studies for the same condition.

See all trials for Oculocerebral hypopigmentation syndrome, Cross type

← Back to all trials